Boston Scientific
BSX
41.58
-0.61
-1.45%
Boston Scientific
US · BSX
#364 by market cap
Listed 1970
41.58
-0.61
-1.45%
Live - 5344 symbols - heartbeat 560s ago
· 2026-10-08 06:38
Pre-market
41.59
+0.02%
After-hours
41.70
+0.29%
Overnight
41.64
+0.14%
- Market cap
- 60.26B
- P/E (TTM)i
- 16.83
- P/Bi
- 2.42
- EPSi
- 1.94
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on BSX?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 21 analysts
Buy
Avg price target
58.58 +40.9%
Price target rangecurrent 41.58
Low48.00
Avg58.58
High70.00
Buy 86%
Hold 14%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-24 | Wells Fargo | -- | HOLD | 48.00 |
| 2026-09-23 | Wells Fargo | -- | HOLD | 48.00 |
| 2026-09-21 | Oppenheimer | -- | BUY | 65.00 |
| 2026-09-20 | BofA Securities | -- | BUY | 54.00 |
| 2026-09-18 | Citi | -- | HOLD | 50.00 |
| 2026-09-17 | TD Cowen | -- | BUY | 56.00 |
| 2026-09-17 | Citi | -- | HOLD | 50.00 |
| 2026-09-14 | BofA Securities | -- | BUY | 54.00 |
| 2026-09-11 | Jefferies | -- | BUY | 60.00 |
| 2026-09-10 | Citi | -- | BUY | 57.00 |
| 2026-09-09 | BTIG | -- | BUY | 56.00 |
| 2026-09-09 | Truist Financial | -- | BUY | -- |
| 2026-09-08 | BofA Securities | -- | BUY | 54.00 |
| 2026-09-08 | Citi | -- | BUY | 61.00 |
| 2026-09-04 | TD Cowen | -- | BUY | 56.00 |
| 2026-08-31 | BofA Securities | -- | BUY | 54.00 |
| 2026-08-28 | TD Cowen | -- | BUY | 56.00 |
| 2026-08-28 | Citi | -- | BUY | 61.00 |
| 2026-08-27 | Truist Financial | -- | BUY | -- |
| 2026-08-25 | TD Cowen | -- | BUY | 56.00 |
| 2026-08-21 | Jefferies | -- | BUY | 60.00 |
| 2026-08-13 | Citi | -- | BUY | 61.00 |
| 2026-08-11 | BofA Securities | -- | BUY | 54.00 |
| 2026-07-31 | Mizuho Securities | -- | BUY | 60.00 |
| 2026-07-31 | Citi | -- | BUY | 61.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
A
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Deteriorating
4
■ Upgrades■ Downgrades
- 0 upgrades vs 4 downgrades among tracked analyst rating changes.
- Most recent: Citi moved from Buy to Hold on 2026-09-17.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-17 | Citi | BUY → HOLD | 50.00 |
| 2026-07-30 | Argus Research | BUY → HOLD | -- |
| 2026-05-29 | Wolfe Research | BUY → HOLD | -- |
| 2026-05-28 | Wells Fargo | BUY → HOLD | 55.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-10-28 | -- | -- | -- |
| 2026/Q2 | 2026-07-29 | -- | ±7.84% | -0.04% (in line) |
| 2026/Q1 | 2026-04-22 | -- | ±5.97% | +8.99% (beat) |
| 2025/Q4 | 2026-02-04 | -- | ±4.71% | -17.59% (beat) |
| 2025/Q3 | 2025-10-22 | -- | ±3.92% | +3.95% (beat) |
| 2025/Q2 | 2025-07-23 | -- | ±5.03% | +4.46% (in line) |
| 2025/Q1 | 2025-04-23 | -- | ±6.17% | +4.07% (in line) |
| 2024/Q4 | 2025-02-05 | -- | ±4.53% | +1.38% (in line) |
| 2024/Q3 | 2024-10-23 | -- | ±6.37% | -0.64% (in line) |
| 2024/Q2 | 2024-07-24 | -- | -- | -1.06% |
| 2024/Q1 | 2024-04-24 | -- | ±5.79% | +5.68% (in line) |
| 2023/Q3 | 2023-10-26 | -- | ±4.07% | -0.42% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:38:27 · For reference only, not investment advice and not tailored to your situation.